Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy.

Brown AW, Holmes T, Fisher M, Tozer GM, Harrity JPA, Kanthou C.

ChemMedChem. 2018 Dec 20;13(24):2618-2626. doi: 10.1002/cmdc.201800567. Epub 2018 Nov 8.

2.

Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes.

Monpara J, Kanthou C, Tozer GM, Vavia PR.

Pharm Res. 2018 Mar 8;35(4):90. doi: 10.1007/s11095-018-2367-8.

PMID:
29520495
3.

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate.

Shepherd J, Fisher M, Welford A, McDonald DM, Kanthou C, Tozer GM.

Oncotarget. 2017 Sep 21;8(56):95648-95661. doi: 10.18632/oncotarget.21172. eCollection 2017 Nov 10.

4.

PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development.

Rumney RMH, Coffelt SB, Neale TA, Dhayade S, Tozer GM, Miller G.

PLoS One. 2017 Dec 8;12(12):e0188591. doi: 10.1371/journal.pone.0188591. eCollection 2017.

5.

Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomography.

Byers RA, Fisher M, Brown NJ, Tozer GM, Matcher SJ.

Biomed Opt Express. 2017 Sep 19;8(10):4551-4567. doi: 10.1364/BOE.8.004551. eCollection 2017 Oct 1.

6.

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.

English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee YC, Bingham K, Hurrell JE, Lyons SK, Kanthou C, Tozer GM.

Cancer Res. 2017 May 15;77(10):2633-2646. doi: 10.1158/0008-5472.CAN-16-0255. Epub 2017 Apr 4.

7.

Direct arterial injection of hyperpolarized 13 C-labeled substrates into rat tumors for rapid MR detection of metabolism with minimal substrate dilution.

Reynolds S, Metcalf S, Cochrane EJ, Collins RC, Jones S, Paley MNJ, Tozer GM.

Magn Reson Med. 2017 Dec;78(6):2116-2126. doi: 10.1002/mrm.26628. Epub 2017 Feb 12.

8.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

9.

Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.

Brown AW, Fisher M, Tozer GM, Kanthou C, Harrity JP.

J Med Chem. 2016 Oct 27;59(20):9473-9488. Epub 2016 Oct 7.

10.

Longitudinal imaging of the ageing mouse.

Dall'Ara E, Boudiffa M, Taylor C, Schug D, Fiegle E, Kennerley AJ, Damianou C, Tozer GM, Kiessling F, Müller R.

Mech Ageing Dev. 2016 Dec;160:93-116. doi: 10.1016/j.mad.2016.08.001. Epub 2016 Aug 13. Review.

11.

Quantitative Estimation of Tissue Blood Flow Rate.

Tozer GM, Prise VE, Cunningham VJ.

Methods Mol Biol. 2016;1430:265-81. doi: 10.1007/978-1-4939-3628-1_18.

12.

Measurement of the acute metabolic response to hypoxia in rat tumours in vivo using magnetic resonance spectroscopy and hyperpolarised pyruvate.

Bluff JE, Reynolds S, Metcalf S, Alizadeh T, Kazan SM, Bucur A, Wholey EG, Bibby BA, Williams L, Paley MN, Tozer GM.

Radiother Oncol. 2015 Sep;116(3):392-9. doi: 10.1016/j.radonc.2015.03.011. Epub 2015 Mar 27.

13.

Relaxation and exchange dynamics of hyperpolarized 129Xe in human blood.

Norquay G, Leung G, Stewart NJ, Tozer GM, Wolber J, Wild JM.

Magn Reson Med. 2015 Aug;74(2):303-11. doi: 10.1002/mrm.25417. Epub 2014 Aug 28.

PMID:
25168398
14.

Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics.

Kanthou C, Dachs GU, Lefley DV, Steele AJ, Coralli-Foxon C, Harris S, Greco O, Dos Santos SA, Reyes-Aldasoro CC, English WR, Tozer GM.

PLoS One. 2014 Aug 13;9(8):e104015. doi: 10.1371/journal.pone.0104015. eCollection 2014.

15.

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.

Williams LJ, Mukherjee D, Fisher M, Reyes-Aldasoro CC, Akerman S, Kanthou C, Tozer GM.

Br J Pharmacol. 2014 Nov;171(21):4902-13. doi: 10.1111/bph.12817.

16.

MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.

Cole LM, Bluff JE, Carolan VA, Paley MN, Tozer GM, Clench MR.

Proteomics. 2014 Apr;14(7-8):890-903. doi: 10.1002/pmic.201300429.

PMID:
24520073
17.

A system for accurate and automated injection of hyperpolarized substrate with minimal dead time and scalable volumes over a large range.

Reynolds S, Bucur A, Port M, Alizadeh T, Kazan SM, Tozer GM, Paley MN.

J Magn Reson. 2014 Feb;239:1-8. doi: 10.1016/j.jmr.2013.10.024. Epub 2013 Nov 22.

18.

Recombinant " IMS TAG" proteins--a new method for validating bottom-up matrix-assisted laser desorption/ionisation ion mobility separation mass spectrometry imaging.

Cole LM, Mahmoud K, Haywood-Small S, Tozer GM, Smith DP, Clench MR.

Rapid Commun Mass Spectrom. 2013 Nov 15;27(21):2355-62. doi: 10.1002/rcm.6693.

PMID:
24097391
19.

Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.

Akerman S, Fisher M, Daniel RA, Lefley D, Reyes-Aldasoro CC, Lunt SJ, Harris S, Bjorndahl M, Williams LJ, Evans H, Barber PR, Prise VE, Vojnovic B, Kanthou C, Tozer GM.

Int J Cancer. 2013 Dec 1;133(11):2563-76. doi: 10.1002/ijc.28281. Epub 2013 Jul 10.

20.

Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input function.

Kazan SM, Reynolds S, Kennerley A, Wholey E, Bluff JE, Berwick J, Cunningham VJ, Paley MN, Tozer GM.

Magn Reson Med. 2013 Oct;70(4):943-53. doi: 10.1002/mrm.24546. Epub 2012 Nov 20.

21.

Online chromatic and scale-space microvessel-tracing analysis for transmitted light optical images.

Reyes-Aldasoro CC, Björndahl MA, Akerman S, Ibrahim J, Griffiths MK, Tozer GM.

Microvasc Res. 2012 Nov;84(3):330-9. doi: 10.1016/j.mvr.2012.09.002. Epub 2012 Sep 14.

PMID:
22982542
22.

Generation of a novel mouse model for the inducible depletion of macrophages in vivo.

Gheryani N, Coffelt SB, Gartland A, Rumney RM, Kiss-Toth E, Lewis CE, Tozer GM, Greaves DR, Dear TN, Miller G.

Genesis. 2013 Jan;51(1):41-9. doi: 10.1002/dvg.22343. Epub 2012 Sep 20.

PMID:
22927121
23.

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.

Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM, Kanthou C.

PLoS One. 2012;7(5):e35231. doi: 10.1371/journal.pone.0035231. Epub 2012 May 2.

24.

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE.

J Clin Invest. 2011 May;121(5):1969-73. doi: 10.1172/JCI44562. Epub 2011 Apr 1.

25.

Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI.

Cole LM, Djidja MC, Bluff J, Claude E, Carolan VA, Paley M, Tozer GM, Clench MR.

Methods. 2011 Aug;54(4):442-53. doi: 10.1016/j.ymeth.2011.03.007. Epub 2011 Mar 23.

26.

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.

Lunt SJ, Akerman S, Hill SA, Fisher M, Wright VJ, Reyes-Aldasoro CC, Tozer GM, Kanthou C.

Int J Cancer. 2011 Oct 15;129(8):1979-89. doi: 10.1002/ijc.25848. Epub 2011 Apr 13.

27.

An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections.

Reyes-Aldasoro CC, Williams LJ, Akerman S, Kanthou C, Tozer GM.

J Microsc. 2011 Jun;242(3):262-78. doi: 10.1111/j.1365-2818.2010.03464.x. Epub 2010 Nov 18.

28.

Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents.

Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Björndahl MA, Evans H, Tozer GM.

Med Eng Phys. 2011 Sep;33(7):805-9. doi: 10.1016/j.medengphy.2010.09.006. Epub 2010 Oct 8.

29.

CAIMAN: an online algorithm repository for Cancer Image Analysis.

Reyes-Aldasoro CC, Griffiths MK, Savas D, Tozer GM.

Comput Methods Programs Biomed. 2011 Aug;103(2):97-103. doi: 10.1016/j.cmpb.2010.07.007. Epub 2010 Aug 5.

30.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

31.

Application of intravital microscopy in studies of tumor microcirculation.

Lunt SJ, Gray C, Reyes-Aldasoro CC, Matcher SJ, Tozer GM.

J Biomed Opt. 2010 Jan-Feb;15(1):011113. doi: 10.1117/1.3281674. Review.

32.

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.

Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA, Bianco A, Vargesson N, Kanthou C, Florence AT, Tozer GM, Kostarelos K.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):3966-71. doi: 10.1073/pnas.0908401107. Epub 2010 Feb 11.

33.

In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer.

Tupper J, Stratford MR, Hill S, Tozer GM, Dachs GU.

Cancer Gene Ther. 2010 Jun;17(6):420-8. doi: 10.1038/cgt.2009.86. Epub 2010 Jan 15.

PMID:
20075982
34.

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Kanthou C, Tozer GM.

Int J Exp Pathol. 2009 Jun;90(3):284-94. doi: 10.1111/j.1365-2613.2009.00651.x. Review.

35.

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.

Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, Hill SA.

Clin Cancer Res. 2009 Jun 1;15(11):3781-90. doi: 10.1158/1078-0432.CCR-08-2906. Epub 2009 May 26.

36.

Quantitative estimation of tissue blood flow rate.

Tozer GM, Prise VE, Cunningham VJ.

Methods Mol Biol. 2009;467:271-86. doi: 10.1007/978-1-59745-241-0_16.

PMID:
19301677
37.

Tumour vascular disrupting agents: combating treatment resistance.

Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA.

Br J Radiol. 2008 Oct;81 Spec No 1:S12-20. doi: 10.1259/bjr/36205483. Review.

PMID:
18819993
38.

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, Greco O, Harris S, Hill SA, Honess DJ, Ireson CR, Pettyjohn KL, Prise VE, Reyes-Aldasoro CC, Ruhrberg C, Shima DT, Kanthou C.

Cancer Res. 2008 Apr 1;68(7):2301-11. doi: 10.1158/0008-5472.CAN-07-2011.

39.

Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm.

Reyes-Aldasoro CC, Akerman S, Tozer GM.

J Microsc. 2008 Jan;229(Pt 1):162-73. doi: 10.1111/j.1365-2818.2007.01877.x.

40.

Tumour targeting by microtubule-depolymerizing vascular disrupting agents.

Kanthou C, Tozer GM.

Expert Opin Ther Targets. 2007 Nov;11(11):1443-57. Review.

PMID:
18028009
41.

Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo.

Reyes-Aldasoro CC, Wilson I, Prise VE, Barber PR, Ameer-Beg M, Vojnovic B, Cunningham VJ, Tozer GM.

Microcirculation. 2008 Jan;15(1):65-79.

PMID:
17952797
42.

Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability.

Gabryś D, Greco O, Patel G, Prise KM, Tozer GM, Kanthou C.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1553-62. Epub 2007 Oct 24.

PMID:
17920784
43.

Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.

Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ.

Lancet Oncol. 2007 Feb;8(2):111-8.

PMID:
17267325
44.

Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.

Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E, Hill SA, Tozer GM.

Int J Oncol. 2007 Feb;30(2):453-60.

PMID:
17203228
45.

Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.

Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, Gunningham SP, Currie MJ, Watson AI, Robinson BA, Tozer GM.

BMC Cancer. 2006 Dec 7;6:280.

46.
47.

Disrupting tumour blood vessels.

Tozer GM, Kanthou C, Baguley BC.

Nat Rev Cancer. 2005 Jun;5(6):423-35. Review.

PMID:
15928673
48.

Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide.

Sonveaux P, Kaz AM, Snyder SA, Richardson RA, Cárdenas-Navia LI, Braun RD, Pawloski JR, Tozer GM, Bonaventura J, McMahon TJ, Stamler JS, Dewhirst MW.

Circ Res. 2005 May 27;96(10):1119-26. Epub 2005 May 5.

PMID:
15879309
49.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK.

Br J Cancer. 2005 May 9;92(9):1599-610.

50.

From bench to bedside for gene-directed enzyme prodrug therapy of cancer.

Dachs GU, Tupper J, Tozer GM.

Anticancer Drugs. 2005 Apr;16(4):349-59. Review.

PMID:
15746571

Supplemental Content

Loading ...
Support Center